May 19, 2026 | Posted By: Sean Estes
On May 18, 2026, the U.S. Supreme Court declined to hear Eli Lilly’s appeal of a $220 million-plus judgment in one of the more closely watched False Claims Act cases in recent years. The decision is an important win for whistleblowers, though it does not fully resolve the constitutional questions swirling around the False Claims Act’s qui tam provisions. If you have witnessed government fraud and are considering whether to come forward, this case is worth understanding.
The Case Behind the Headlines
The case began in 2014, when Ronald Streck, a pharmacist and attorney, filed a whistleblower lawsuit under the False Claims Act against Eli Lilly. Streck alleged that Eli Lilly had cheated the Medicaid Drug Rebate Program by manipulating the calculation of the “average manufacturer’s price” for certain drugs. Specifically, Streck claimed that, over time, when wholesalers paid higher prices for Eli Lilly’s drugs, those increases were not factored into the pricing formula the company submitted to the federal government. The result, according to Streck, was that Eli Lilly systematically underpaid the drug rebates it owed to Medicaid by roughly $61 million over three years.
In 2018, the Department of Justice declined to intervene in the case, meaning the government chose not to take over prosecution. Streck and his legal team continued the case on their own. In 2022, after a full trial, a federal jury in Illinois found Eli Lilly liable for knowingly defrauding the government. The jury awarded $61 million in damages, which was automatically trebled (or tripled) to $183 million under the False Claims Act’s penalty provisions. With accumulated interest, the total judgment now exceeds $220 million.
Eli Lilly appealed, and in September 2025, the Seventh Circuit Court of Appeals unanimously upheld the verdict. That set the stage for Eli Lilly’s petition to the Supreme Court.
The Constitutional Challenge, For Now
What made this case unusual was not just the dollar amount. Eli Lilly mounted a direct constitutional attack on the qui tam mechanism itself, arguing that allowing private citizens to sue on behalf of the government violates the Appointments Clause of the U.S. Constitution. The company characterized whistleblowers like Streck as “private bounty hunters” who are not appointed by, removable by, or accountable to the President.
This argument did not originate with Eli Lilly. It traces back to a 2023 dissent by Justice Clarence Thomas in a case called U.S. ex rel. Polansky v. Executive Health Resources, in which Thomas suggested that qui tam proceedings raise serious constitutional questions when the government declines to intervene. Since then, defendants in False Claims Act cases across the country have seized on this language in an effort to undermine the qui tam framework.
The Supreme Court’s refusal to hear Eli Lilly’s case does not establish new legal precedent in the traditional sense, but it does carry practical weight. It leaves the Seventh Circuit’s ruling intact as binding authority, and it means that whistleblowers can continue to bring qui tam actions with confidence in every federal circuit. That said, the denial should not be read as the Supreme Court endorsing the constitutionality of qui tam. The justices may have a different vehicle in mind.
The Eli Lilly denial is especially significant because the constitutional question is far from settled. In September 2024, U.S. District Judge Kathryn Kimball Mizelle of the Middle District of Florida became the first federal judge in the country to rule that the False Claims Act’s qui tam provisions are unconstitutional, holding that whistleblower relators function as officers of the United States who must be formally appointed under Article II of the Constitution. That case, United States ex rel. Zafirov v. Florida Medical Associates, is now on appeal before the Eleventh Circuit Court of Appeals, which heard oral arguments in December 2025 and has not yet issued a decision. If the Eleventh Circuit upholds Judge Mizelle’s ruling, it would create a split among the federal appeals courts and dramatically increase the likelihood that the Supreme Court takes up the issue directly. By declining to hear Eli Lilly’s challenge now, the justices may simply be waiting for the Eleventh Circuit to weigh in before deciding whether to address the constitutionality of qui tam head-on.
Why This Matters for Potential Whistleblowers
If you have been hesitant to come forward because of concerns about whether the False Claims Act will hold up in court, this decision should offer measured reassurance. The Supreme Court passed on one high-profile opportunity to weaken qui tam rights, and the law remains fully enforceable while the constitutional debate plays out.
The government recovered more than $6.8 billion through False Claims Act cases in fiscal year 2025 alone, and whistleblowers received over $330 million in relator share awards. Those numbers are not shrinking.
In fact, the opposite is happening. Qui tam filings have hit record highs for three consecutive years. Nearly 1,300 whistleblower lawsuits were filed in fiscal year 2025, and the Department of Justice is on pace to exceed that number again in 2026. The DOJ recently launched a new initiative, FOCUS (Fraud Oversight through Careful Use of Statistics), specifically designed to strengthen its partnership with whistleblowers who use data analysis to identify fraud. That initiative, announced on April 30, 2026, is a clear signal that the government is investing more, not less, in False Claims Act enforcement.
Several things are worth highlighting for anyone considering filing a qui tam lawsuit:
- The government does not have to intervene for you to win. In this case, the DOJ declined to intervene in 2018. Streck’s legal team litigated the entire case on their own, through trial, appeal, and a Supreme Court petition, and prevailed at every stage. While government intervention generally increases a case’s chances of success, a strong case with experienced counsel can succeed without it.
- The financial stakes are real. Under the False Claims Act, a successful whistleblower is entitled to between 15 and 25 percent of the government’s recovery when the government intervenes, and between 25 and 30 percent when the whistleblower’s team handles the case independently. In Streck’s case, the judgment exceeded $220 million. Across his career as a relator, Streck’s successful lawsuits against drug manufacturers have recovered more than $350 million for the Medicaid program.
- The law protects you from retaliation. The False Claims Act contains robust anti-retaliation provisions that prohibit employers from firing, demoting, suspending, threatening, or otherwise retaliating against employees who report fraud. If retaliation occurs, you may be entitled to reinstatement, double back pay, and attorney’s fees.
The Bigger Picture: FCA Enforcement Is Accelerating
The Eli Lilly decision does not exist in a vacuum. It comes during one of the most active periods of False Claims Act enforcement in the statute’s history. Beyond the record qui tam filing numbers and the new FOCUS initiative, the DOJ has also established a National Fraud Enforcement Division and a Civil Rights Fraud Task Force. Healthcare companies, government contractors, and businesses receiving federal funds are all facing heightened scrutiny.
For companies doing business with the government, the takeaway is equally important. This is the wrong time to cut corners on compliance. Whistleblowers are empowered, the government is investing in enforcement tools, and courts are sustaining large judgments. Companies should be conducting rigorous internal audits, ensuring the accuracy of all claims and certifications submitted to federal programs, and maintaining thorough documentation. If a potential problem surfaces, engaging experienced counsel early can make the difference between a manageable compliance issue and a devastating False Claims Act verdict.
Contact Hoyer Law Group
Hoyer Law Group has deep experience representing whistleblowers in False Claims Act cases, from healthcare fraud to government contracting fraud and beyond. Our attorneys have recovered millions of dollars for clients and the American taxpayer. If you have knowledge of fraud against the government, or if you are a company that needs help strengthening its compliance program, contact Hoyer Law Group for a confidential evaluation.
Contact us online or call (844) 531-0082.
This blog is for general informational purposes only and does not constitute legal advice. For advice specific to your situation, please consult a qualified attorney.